PROPELLON THERAPEUTICS
Propellon Therapeutics is developing and commercializing novel cancer therapies targeting the WDR5 protein, essential for assembly of methyltransferase complexes and proper histone modification. The overexpression of WDR5 and resulting deregulation of epigenetic mechanisms are implicated in various cancers and correlated with poor patient survival. Established by FACIT, Propellon’s WDR5 inhibitor platform arises from discoveries, research and innovations originating from OICR.
PROPELLON THERAPEUTICS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2016-06-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Total Employee:
1+
Status:
Active
Total Funding:
3 M USD
Similar Organizations
Parthenon Therapeutics
Parthenon Therapeutics is a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Current Employees Featured
Investors List
Jed McCaleb
Jed McCaleb investment in Seed Round - Propellon Therapeutics
FACIT
FACIT investment in Seed Round - Propellon Therapeutics
Dan Schultz
Dan Schultz investment in Seed Round - Propellon Therapeutics
Rami Essaid
Rami Essaid investment in Seed Round - Propellon Therapeutics
More informations about "Propellon Therapeutics"
Propellon Therapeutics to Accelerate WDR5 Inhibitor …
Jun 23, 2016 Propellon Therapeutics is developing and commercializing novel cancer therapies targeting the WDR5 protein, essential for assembly of methyltransferase complexes and proper histone modification. The …See details»
First-in-class drug for blood cancers discovered by …
Jan 29, 2019 “FACIT’s resources and funding ensured Propellon moved to the next stage of development and growth in Ontario,” says O’Neill. “The seed investment allowed the start-up to maintain momentum and begin to identify …See details»
Propellon Therapeutics - Ontario Institute for Cancer Research
Organization. validation. Search. Patient Partnership; FAQs; Careers; Français; About. Overview; Leadership; Reports; Commercialization and FACIT; Achievements; ... Propellon Therapeutics …See details»
Propellon Company Profile 2025: Valuation, Investors, Acquisition ...
Propellon General Information Description. Developer of cancer therapies intended to target WDR5 protein. The company is working on WDR5 protein which is essential for assembly of …See details»
Propellon Therapeutics to Accelerate WDR5 Inhibitor …
FACIT has announced the creation of a new Ontario biotechnology company, Propellon Therapeutics Inc. (“Propellon” or “the Company”), to manage the development and …See details»
Propellon Therapeutics Inc Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Propellon Therapeutics Inc of Toronto, ON. Get the latest business insights from Dun & Bradstreet.See details»
Propellon Therapeutics to Accelerate WDR5 Inhibitor ... - Newswire
Jun 23, 2016 Propellon Therapeutics is developing and commercializing novel cancer therapies targeting the WDR5 protein, essential for assembly of methyltransferase complexes and …See details»
Propellon Therapeutics - Funding, Financials, Valuation & Investors
Propellon Therapeutics is developing and commercializing novel cancer therapies targeting the WDR5 protein. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How …See details»
Propellon Therapeutics Inc - Company Profile and News
Company profile page for Propellon Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
Propellon Therapeutics - Contacts, Employees, Board Members, …
Organization. Propellon Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. About. …See details»
Propellon Therapeutics - Products, Competitors, Financials, …
The therapy was held by Propellon Therapeutics, a virtual company FACIT seed funded in 2016 and then transferred to its Triphase group to focus on developing a portfolio of WDR5-targeted …See details»
FACIT Announces Investment in Propellon Therapeutics
Mar 22, 2017 Seed financing of CAD$3.0M positions first-in-class WDR5 cancer therapy for clinical development TORONTO, March 22, 2017 /CNW/ – FACIT announced a seed stage …See details»
Research programme: WDR5 inhibitors - Propellon …
Propellon Therapeutics and Ontario Institute for Cancer Research are developing WDR5 inhibitors for the treatment of cancer. The WDR5 protein is critical for Research programme: WDR5 …See details»
FACIT Announces Investment in Propellon Therapeutics - PR …
Mar 22, 2017 Propellon Therapeutics is developing and commercializing novel cancer therapies targeting the WDR5 protein, essential for assembly of methyltransferase complexes and …See details»
Toronto advised FACIT and Propellon on a partnership between …
Feb 5, 2019 Our Toronto office advised FACIT and its subsidiary, Propellon, on a partnership between Triphase Accelerator and Celgene to research, develop and commercialize a top tier …See details»
FACIT Announces Investment in Propellon Therapeutics
TORONTO, ON (March 22, 2017) – FACIT announced a seed stage investment in Propellon Therapeutics (the “Company” or “Propellon”), a start-up created by FACIT focused on …See details»
Celgene partners Triphase for preclinical blood cancer candidate
Jan 30, 2019 FACIT seed financed Propellon Therapeutics to commercialise the preclinical candidate, which targets the WDR5 protein that is associated with the formation and activity of …See details»
Peptone Announces Key Leadership Appointments to Progress …
1 day ago Peptone is developing novel therapeutics targeting intrinsically disordered proteins (IDPs) to treat diseases through a pioneering approach that starts with studying the structural …See details»
Peptone Announces Key Leadership Appointments to Progress …
2 days ago LONDON and BELLINZONA, Switzerland, Jan. 9, 2025 /PRNewswire/ -- Peptone, a biotech company developing novel therapeutics targeting intrinsically disordered proteins …See details»
FACIT Announces Investment in Propellon Therapeutics - Newswire
Mar 22, 2017 /CNW/ - FACIT announced a seed stage investment in Propellon Therapeutics (the "Company" or "Propellon"), a start-up created by FACIT focused on developing a...See details»